問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Cardiovascular Diseases

更新時間：2026-06-01

張建偉
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張建偉

List

5Cases

2025-10-01 - 2030-06-30

Active
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

  • Condition/Disease

    Diabetes Mellitus, Type 2 Hypertension Cardiovascular Diseases

  • Test Drug

    BI 690517 (Vicadrostat) or matching placebo Empagliflozin

Participate Sites
13Sites

Recruiting13Sites

2026-06-01 - 2030-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

  • Condition/Disease

    Sacroiliac Joint Pain

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
14Sites

Recruiting14Sites

2026-09-01 - 2029-06-30

Phase II

Not yet recruiting
A phase 2, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFrEF).

  • Condition/Disease

    Heart failure with reduced ejection fraction

  • Test Drug

    CRD-4730

Participate Sites
4Sites

Not yet recruiting4Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    錠劑 膜衣錠

Participate Sites
12Sites

Not yet recruiting1Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    錠劑 膜衣錠

Participate Sites
10Sites

Not yet recruiting1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB